IMPAACT P1032 |
The purpose of this study was to determine which of 3 different anti-HIV drug regimens given to HIV infected pregnant women during and after their pregnancies is most effective in reducing the selection of nevirapine (NVP) resistance mutations after exposure to a single dose of nevirapine for the prevention of mother to child transmission of HIV. Participants were randomly assigned to one of three study arms. All study participants will receive nevirapine and zidovudine. In one arm, participants received didanosine (ddI) and LPV/r for 7 days postpartum; in another arm, they received didanosine for 30 days postpartum. And in the third arm, they received didanosine and LPV/r for 30 days postpartum.
This study was performed in collaboration with the IMPAACT network.
Results showed that the three regimens were able to virtually eliminate the risk of selection of resistance mutations. With this post exposure treatment, women can benefit from nevirapine for the protection of their child without compromising their own future treatment.
For further information please refer to: ClinicalTrials.gov NCT00109590
This study was performed in collaboration with the IMPAACT network.
Results showed that the three regimens were able to virtually eliminate the risk of selection of resistance mutations. With this post exposure treatment, women can benefit from nevirapine for the protection of their child without compromising their own future treatment.
For further information please refer to: ClinicalTrials.gov NCT00109590
